Mozobil Boosts Stem Cells Before Bone Marrow Transplants

Posted on 12/19/2008, 09:36
By -- Scott Roberts

Could help people with certain forms of blood cancer

FRIDAY, Dec. 19 (HealthDay News) -- The Genzyme Corp. drug Mozobil (plerixafor) has been approved by the U.S. Food and Drug Administration to boost a person's blood stem cell count before a bone marrow transplant, the agency said in a news release.

A bone marrow transplant is often performed in people with certain forms of cancer -- multiple myeloma and non-Hodgkin's lymphoma. Before getting high doses of chemotherapy or radiation, people with these forms of cancer may be advised to have blood stem cells collected so the cells can be re-infused after the therapy. Mozobil helps increase the number of stem cells before collection.

The most frequent side effects of Mozobil reported during clinical testing included diarrhea, nausea, fatigue, reactions near the injection site, headache, joint pain and dizziness.

More information

The U.S. Food and Drug Administration has more about this drug's approval history.

Copyright © 2008 ScoutNews, LLC. All rights reserved.

More news in Leukemia...

BigHealthTree.com Disclaimer

Bighealthtree.com Does Not Provide Medical Advice. This site, including the above information, is for informational purposes only and is not a substitute for professional medical or health advice. Always seek the advice of your physician or a qualified health or medical professional before starting any new treatment, changing existing treatment, or altering your current exercise and/or diet program. If you think you are having a medical emergency, call 911 (or the emergency services in your area) or your doctor immediately.

Rating: 3.1 / 5 (118 votes)
Rate the article:
1/52/53/54/55/5

Comments (0):

Be the first to comment on this article.

Post a comment

Name

Subject

Text in the image

Comment